NasdaqGM:PRCTMedical Equipment
Why PROCEPT BioRobotics (PRCT) Is Up 9.6% After Reaffirming 2026 Revenue Guidance Despite Wider Losses
In the second quarter of 2026, PROCEPT BioRobotics reported sales of US$94.5 million, up from US$79.18 million a year earlier, while its net loss widened to US$26.86 million and it reiterated full-year 2026 revenue guidance of US$390 million to US$410 million alongside an expected net loss of US$96 million to US$91 million.
This combination of stronger top-line growth but larger losses, together with analyst concerns about slower procedure trends, competition and legal overhang, has...